Verified facts about the outbreak. Each entry has a confidence score and source attribution. Pipeline writes corroborate or supersede entries as new intel comes in.
ANDV causes Hantavirus Cardiopulmonary Syndrome (HCPS/HPS), affecting primarily the lungs and heart. This is distinct from Hemorrhagic Fever with Renal Syndrome (HFRS) caused by Old World hantaviruses (Hantaan, Dobrava, Seoul, Puumala) which primarily affects the kidneys. HCPS has a significantly higher case fatality rate (30-50%) compared to most HFRS variants (1-15%).
Phase 1 — PRODROMAL (1-5 days): Fever, chills, severe muscle aches (myalgias), headache, malaise, gastrointestinal distress (nausea, vomiting, abdominal pain, diarrhea). Clinically indistinguishable from common flu. This is when patients are most infectious. Phase 2 — CARDIOPULMONARY (2-7 days): Sudden respiratory failure. Massive pulmonary edema and hypoxia. Cardiovascular collapse with tachycardia, arrhythmias, cardiogenic shock. Hypotension. Death typically occurs within 24-48 hours of cardiopulmonary phase onset. Phase 3 — RECOVERY (weeks to months): For survivors, gradual improvement. Persistent dyspnea can last 1-2 years. Polyuria during convalescence. Complete recovery is common with appropriate critical care.
No specific antiviral exists for HCPS. Ribavirin showed NO significant mortality reduction in meta-analysis (RR 0.99, 95% CI 0.60-1.61) — it is not recommended. Treatment is supportive: intensive hemodynamic monitoring, aggressive fluid management, mechanical ventilation, blood product support for coagulopathy. ECMO (extracorporeal membrane oxygenation) is the most effective intervention with ~80% survival rate when initiated early, before hemodynamic instability develops. VA-ECMO serves as a bridge to recovery during the acute cardiopulmonary phase.
Death in HCPS results from a virally-triggered hyperinflammatory cytokine storm that disrupts pulmonary microvascular barriers WITHOUT direct destruction of endothelial cells. The virus infects vascular endothelial cells and macrophages, triggering massive TNF-alpha, IFN-gamma, and nitric oxide release. This increases capillary permeability, causing catastrophic fluid leakage into the lungs (pulmonary edema). Simultaneously, inflammatory mediators cause myocardial depression (cardiogenic shock). The combination of flooded lungs and a failing heart is what kills patients, often within hours.
No antiviral drug works against hantavirus — ribavirin showed zero benefit in clinical trials. Treatment is purely supportive. ECMO (a heart-lung bypass machine) achieves 80% survival when started early, before cardiovascular collapse. Without ECMO access, mortality is significantly higher.
There is no licensed vaccine for any New World hantavirus, including Andes virus (ANDV). The most advanced candidate is a DNA vaccine developed at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) by Jay Hooper and colleagues; Phase 1 trials in humans for ANDV (and two other hantavirus strains) have shown induction of neutralizing antibodies, considered necessary for protection. Separately, Moderna confirmed (May 8, 2026) that it has been collaborating with USAMRIID and the Vaccine Innovation Center at Korea University College of Medicine on early-stage hantavirus mRNA vaccine research that began before the MV Hondius outbreak. Subject-matter experts cited in Nature and NBC estimate that without an Operation Warp Speed-scale federal push, full clinical development to licensure could take a decade or more. Online conspiracy claims that Moderna started this work in foreknowledge of the 2026 outbreak are false; the work predates and is consistent with routine biodefense research.
Incubation period ranges from 9 to 40 days (average 18 days). Starts with fever, headache, and muscle pain that looks like flu. Then rapidly progresses to severe breathing difficulty and cardiovascular collapse. This long incubation is why contacts are monitored for 42 days.
Case fatality rate of 30-50% — one of the deadliest infectious diseases when contracted. MV Hondius outbreak: 3 deaths from ~9 cases (33%). Death occurs from massive lung fluid buildup and heart failure, typically within 24-48 hours of respiratory symptoms starting.
RT-PCR on serum can detect ANDV RNA 5-15 days before symptom onset or antibody detection — critical for early diagnosis in exposed contacts. IgM and IgG antibodies appear by approximately day 10 after symptom onset. IgM persists for months; IgG persists for years and likely confers long-term immunity. Both RT-PCR and serology should be used in parallel for exposed contacts developing fever within the incubation period.
Historical CFR for ANDV infections ranges from 30-50%, significantly higher than most infectious diseases. The MV Hondius cluster shows 3 deaths out of ~9 total cases as of May 8 2026. CFR varies by outbreak and access to critical care — early ECMO access dramatically improves survival.
Initial flu-like phase (3-7 days): fever, headache, muscle pain, gastrointestinal upset. Patient typically improves briefly, then deteriorates rapidly into the cardiopulmonary phase: shortness of breath, fluid in the lungs, low blood pressure. Severe cases progress to hantavirus pulmonary syndrome (HPS) with cardiogenic shock. Death, when it occurs, usually follows the acute pulmonary phase by 24-48 hours.
Incubation period ranges from 9 to 40 days with a median of approximately 18 days. This long and variable incubation complicates contact tracing — exposed individuals may not develop symptoms for over a month. WHO recommends a 42-day surveillance window for MV Hondius contacts.
No licensed hantavirus vaccine anywhere in the world. Moderna has a pre-existing mRNA collaboration with USAMRIID and Korea University but it is preclinical (animal studies only). Any vaccine is years from human availability. USAMRIID also has a Phase 1 DNA vaccine candidate.
No FDA-, EMA-, or WHO-prequalified hantavirus vaccine exists. A small number of ANDV-targeted candidates (DNA-based and recombinant glycoprotein) are in phase I/II trials, primarily in Argentina and Chile. None are expected to reach licensure within the MV Hondius surveillance window.
Higher severity associated with: age 60+, pre-existing hypertension, diabetes, smoking history, higher viral load at presentation, concurrent liver injury. American Indian women aged 40-64 have the highest demographic risk for hantavirus exposure in the Americas. Delayed hospital access (rural settings) worsens outcomes.
Most HCPS survivors achieve complete recovery. Persistent respiratory difficulties (dyspnea) can last 1-2 years. Polyuria common during convalescence. Long-term follow-up recommended for kidney function, blood pressure, and cardiovascular risk. Infection appears to confer lasting immunity via persistent IgG antibodies. Genetic factors may influence both acute severity and long-term complications.
On 9 May 2026 ECDC published formal operational guidance for managing passengers and crew linked to the MV Hondius Andes hantavirus outbreak. Asymptomatic passengers are classified as high-risk contacts as a precautionary measure (subject to per-case exposure assessment). Recommended PPE during medical interactions: FFP2 respirators, gloves, gowns, eye protection. Guidance addresses contact classification, testing protocols, infection prevention, and risk communication for EU/EEA public-health authorities and clinicians involved in disembarkation, transfer, and care.
On May 8 2026 the U.S. CDC confirmed it will dispatch personnel to the Canary Islands to meet U.S. citizens aboard MV Hondius when the ship arrives Sunday May 10, then escort them to the National Quarantine Unit at the University of Nebraska Medical Center. UNMC and Nebraska Medicine confirmed the Nebraska Biocontainment Unit and National Quarantine Unit are 'staffed and ready' to safely provide care if needed. As of May 8, no U.S. residents have been symptomatic.
On 9 May 2026 UK Health Security Agency strategy was confirmed by three independent Tier-2/3 outlets (Reuters, BBC, The Guardian): the ~24 British nationals returning from the MV Hondius will be flown home from Tenerife after on-site clinical screening and isolated at a designated hospital site, rather than home quarantine. This is a stricter posture than the US (mixed UNMC Nebraska + state home-monitoring) and Ireland (case-by-case) approaches. Driven by UKHSA precautionary stance for an ANDV exposure cohort with elevated incubation-period uncertainty.
Canary Islands president Fernando Clavijo announced May 7-8 2026 that MV Hondius will remain at anchorage offshore Tenerife rather than berthing at the Port of Granadilla. Passengers will be evacuated by tender boat into a cordoned-off area, then bused to Tenerife South airport for onward repatriation flights. The 14 Spanish passengers are to be transferred to a military hospital after onboard examination. Spain framed the operation as compliant with international law and humanitarian obligations. The evacuation must complete between Sunday May 10 and Monday May 11 because deteriorating weather will force the vessel to depart.
On May 7 2026 the French Health Ministry stated that 8 French nationals not aboard the MV Hondius have been identified as close contacts of a confirmed case. One French citizen with benign symptoms was placed in isolation pending tests, identified as a contact case from the Saint Helena-Johannesburg flight (the leg before KL592). France is one of nine EU/EEA states represented among MV Hondius passengers.
UKHSA (UK Health Security Agency) confirmed on May 7-8 2026 that two UK residents are self-isolating after possible exposure linked to MV Hondius. The UK government is chartering a plane to repatriate the roughly two dozen British nationals still aboard the vessel. UKHSA is following standard contact-tracing protocols for returnees, leveraging the 42-day surveillance window recommended by WHO and ECDC.
Reproduction number below 1 — each infected person infects fewer than 1 other person on average. Outbreaks burn out on their own. The 2018 Epuyen outbreak (36 cases) and 1996 El Bolson outbreak (18 cases) both self-limited. This is NOT another COVID (COVID R0 was 2-3+).
KLM flight KL592 (Johannesburg-Amsterdam, April 25-26 2026) became a secondary exposure event when MVH-002 boarded while acutely symptomatic and was removed after 45 minutes. 60 passengers identified for tracing, 5 classified high-risk. A flight attendant who had direct close contact during boarding/removal was hospitalized May 7 with mild symptoms but TESTED NEGATIVE (confirmed by WHO May 8). No other KL592 contacts have tested positive. This is significant epidemiological evidence: even direct contact with a symptomatic ANDV patient in an enclosed aircraft was insufficient for transmission during brief exposure.
Index couple (MVH-001, MVH-002) traveled through South America Nov 2025-Apr 2026. Crossed into Argentina via Neuquen province (endemic ANDV area) Jan 31. Also visited Misiones (endemic area). Suspected primary exposure during birdwatching excursion to a landfill near Ushuaia where MVH-001 likely inhaled aerosolized rodent excreta. The couple then boarded MV Hondius April 1, carrying the infection aboard.
As of May 8 2026: 6 confirmed cases (MVH-001, MVH-002, MVH-004, MVH-005, MVH-006, MVH-009), 1 confirmed secondary (CH-001), 2-3 suspected (MVH-003, MVH-007, MVH-008, TDC-001). 3 deaths. Countries with confirmed/suspected cases: Netherlands, South Africa, Cape Verde, Switzerland, Germany, UK, Spain. Countries monitoring contacts: US (5 states), Canada, Singapore, Denmark, New Zealand, Turkey, France, Saint Kitts and Nevis. WHO global risk assessment: LOW.
Estimated reproduction number for the MV Hondius person-to-person chain is below 1 (~0.7), based on ~9 cases arising from ~150 close-contact-eligible passengers and crew over 3+ weeks of prolonged shared exposure. Secondary attack rate among household contacts (CH-001 dyad) is 1/2. R0 < 1 means transmission chains are expected to burn out without sustained close contact.
September-December 1996 in El Bolson, Argentina. 18 cases linked epidemiologically. Index case September 22. Three physicians developed HPS 27-28 days after treating the index patient — providing the first direct genetic evidence of human-to-human hantavirus transmission. Low rodent population density at the time supported person-to-person as the primary mechanism rather than a common environmental source.
Epuyen, Chubut province, Argentina. November 2018-January 2019. 36 cases, 11 deaths. Published in NEJM. Demonstrated superspreader dynamics: Patient #1 infected 5 people in 90 minutes at a birthday party (1-4 foot distances). Three symptomatic individuals generated roughly two-thirds of all cases. High viral load and liver injury were associated with transmission capacity. This outbreak established the R0 below 1 estimate for ANDV.
1996 El Bolson, Rio Negro province, Argentina: 20 cases, first documented person-to-person ANDV transmission; cluster burned out without sustained spread. 2018 Epuyen, Chubut province, Argentina: 36 cases including a documented superspreading event; also self-limited. Both outbreaks featured close-contact transmission within households and healthcare settings rather than community spread, consistent with R0 < 1.
The molecular basis remains unknown. Compared to Sin Nombre virus (SNV), ANDV produces higher mucosal viral burdens and is uniformly lethal in Syrian hamster models (SNV is not). ANDV more effectively interferes with interferon signaling. The unique capacity may relate to higher respiratory tract viral replication enabling aerosol generation, but this has not been definitively proven.
Nov 27 2025: Dutch couple begins 4-month South America road trip. Jan 31: Enter Argentina via Neuquen. Late Mar: Birdwatching at Ushuaia landfill (exposure). Apr 1: Board MV Hondius, Ushuaia (~114 passengers). Apr 6: MVH-001 symptom onset. Apr 11: MVH-001 dies aboard ship. Apr 13-15: Ship at Tristan da Cunha (TDC-001 possible exposure). Apr 24: Ship at Saint Helena, 30 passengers disembark, MVH-001 body offloaded, MVH-002 evacuated. Apr 25: MVH-002 boards KL592 Johannesburg-Amsterdam, removed after 45 min. Apr 26: MVH-002 dies Johannesburg. Apr 27: Ship at Ascension Island, MVH-006 evacuated to South Africa. Apr 28: MVH-003 onset. May 2: MVH-003 dies aboard, MVH-004 PCR confirmed. May 3-6: Ship at Cape Verde. May 4: CH-001 symptomatic in Zurich. May 6: Three evacuations from ship (MVH-004 to Leiden, MVH-007 to Dusseldorf, MVH-008 diverted to Gran Canaria). CH-001 hospitalized. May 7: WHO press briefing. May 8: KL-001 flight attendant confirmed negative. Ship heading to Tenerife (expected May 9).
Species: Orthohantavirus andesense. Genus: Orthohantavirus. Family: Hantaviridae. Order: Bunyavirales. ANDV is a New World hantavirus endemic to southern South America, first isolated in 1995 in southern Chile.
The only hantavirus capable of spreading person-to-person. First isolated 1995 in Chile. Endemic to southern Argentina and Chile. No mutations detected in the MV Hondius isolates vs. reference Patagonian strain.
Andes orthohantavirus belongs to the family Hantaviridae, order Bunyavirales. The family contains New World (Sin Nombre, Andes, Hantaan) and Old World (Puumala, Seoul) species. ANDV is grouped with the New World hantaviruses that cause hantavirus pulmonary syndrome (HPS).
Three negative-sense single-stranded RNA segments totaling ~12.1 kb. Small segment (S, ~1.87 kb): encodes nucleoprotein and an interferon-inhibiting non-structural protein. Medium segment (M, ~3.67 kb): encodes glycoprotein precursor cleaved into spike proteins Gn and Gc during virion assembly. Large segment (L, ~6.56 kb): encodes RNA-dependent RNA polymerase (RdRp) for genome transcription and replication.
Natural reservoir: Oligoryzomys longicaudatus (long-tailed pygmy rice rat), found in southern Argentina and Chile. Humans get infected by inhaling aerosolized rodent urine, feces, or saliva — typically in enclosed spaces like barns, cabins, or landfills. The MV Hondius index case was likely exposed at a landfill near Ushuaia during a birdwatching excursion.
Primary reservoir is the long-tailed pygmy rice rat (Oligoryzomys longicaudatus), endemic to southern Argentina and Chile. Rodents are asymptomatic carriers. Virus shed in urine, feces, and saliva. Human infection occurs via inhalation of aerosolized excreta in enclosed spaces (barns, cabins, landfills).
Mostly spherical or pleomorphic particles, 80-160 nm diameter. Lipid bilayer envelope (~5 nm) with embedded Gn/Gc spike glycoproteins in lattice pattern. Interior contains helical nucleocapsids. Susceptible to household bleach and 70% ethanol. Killed by solar radiation and ozone.
Preliminary sequencing of ANDV from MV Hondius cases shows no atypical mutations compared to reference Patagonian strain. Sequence identity confirmed between MVH-001 and MVH-002 (no inter-host mutation). Full genomic analysis ongoing.
Aerosolized virus can survive up to 2 weeks at moderate temperatures in low-UV environments. Infectivity lost after 5-11 days at 23C. Survives hours to days in dirt, dust, and rodent nests. Rapidly inactivated by sunlight, bleach, and 70% ethanol.
Singapore's Communicable Diseases Agency (CDA) announced May 7 2026 that returnees from MV Hondius are being held under the following protocol: immediate isolation at the National Centre for Infectious Diseases (NCID) and PCR testing for hantavirus. If PCR-negative, contacts are quarantined for 30 days from date of last exposure (covering the period when the majority of cases become symptomatic), retested before release, then placed on phone surveillance for the remaining 45 days from last exposure (the maximum hantavirus incubation period). If PCR-positive, they remain hospitalised given the severity of the disease. Two Singapore residents (67-year-old citizen, 65-year-old PR) who were on the same KL592 flight as a confirmed case are currently isolated at NCID.
WHO assessed overall global risk as LOW on May 7. ANDV requires close prolonged contact for transmission, limiting pandemic potential. R0 below 1 means sustained community spread is not expected. WHO deployed 2,500 diagnostic kits to 5 countries and is coordinating passenger tracing across 23 nationalities.
CDC classified the outbreak as Level 3 (lowest severity). Risk to the American public assessed as extremely low. Five US states monitoring returned MV Hondius passengers: California, Georgia, Arizona, Texas, Virginia. No confirmed US cases as of May 8 2026.
WHO and ECDC recommend 42-day surveillance for all MV Hondius contacts, reflecting the long incubation period (up to 40 days). Contacts are asked to self-monitor for fever, myalgia, and respiratory symptoms and seek immediate medical attention if symptomatic.
Andes orthohantavirus is unique among all known hantaviruses in its confirmed ability to transmit between humans. No other hantavirus (Sin Nombre, Hantaan, Seoul, Dobrava, Puumala) has documented person-to-person spread. This was first proven genetically in the 1996 El Bolson outbreak in Argentina.
Primary transmission route is inhalation of aerosolized rodent urine, feces, or saliva in enclosed spaces (barns, cabins, abandoned buildings, landfills). Highest risk activities: cleaning enclosed spaces with rodent infestations, farming, forestry work. The MV Hondius index case (MVH-001) was likely exposed at a landfill near Ushuaia during a birdwatching excursion.
Transmission between humans requires close and prolonged contact: direct physical contact, shared enclosed living spaces (cabins, bedrooms), or prolonged face-to-face interaction enabling respiratory secretion exposure. Casual or brief contact is insufficient. The KLM KL592 flight attendant case (May 2026) confirms this: despite 45 minutes of direct contact with an acutely symptomatic patient in an aircraft, the attendant tested negative. No evidence of airborne community spread.
Requires sustained close contact with an infected person or their bodily fluids. NOT airborne. Brief contact is insufficient — a KLM flight attendant had 45 minutes of direct contact with a symptomatic patient and tested negative (WHO confirmed). Cannot spread through casual interaction, shared spaces, or brief encounters.
The 2018 Epuyen outbreak in Argentina (36 cases, 11 deaths) demonstrated superspreader dynamics. Patient #1 infected 5 people in approximately 90 minutes at a birthday party, with infections occurring at distances of 1-4 feet. Transmission was associated with high viral load and concurrent liver injury. Three symptomatic persons accounted for roughly two-thirds of all infections.
Person-to-person transmission occurs primarily during the early prodromal phase, around day 1 of symptom onset when viral load peaks. This is before severe cardiopulmonary symptoms develop, meaning carriers may appear to have only a mild flu-like illness when they are most infectious.
The basic reproduction number (R0) for ANDV person-to-person transmission is estimated below 1, meaning it cannot sustain epidemic-level spread in a general population. Outbreaks are driven by individual superspreader events rather than sustained chains. In the 2018 Epuyen outbreak (Argentina), just 3 symptomatic individuals infected the majority of 36 total cases.